Results 51 to 60 of about 1,923,383 (256)

A TCR-based Chimeric Antigen Receptor

Scientific Reports, 2017
Effector T cells equipped with engineered antigen receptors specific for cancer targets have proven to be very efficient. Two methods have emerged: the Chimeric Antigen Receptors (CARs) and T-cell Receptor (TCR) redirection.
Even Walseng, Hakan Köksal, Ibrahim M. Sektioglu, Anne Fåne, Gjertrud Skorstad, Gunnar Kvalheim, Gustav Gaudernack, Else Marit Inderberg, Sébastien Wälchli   +8 more
doaj   +1 more source

Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas

New England Journal of Medicine, 2017
Background Patients with diffuse large B‐cell lymphoma or follicular lymphoma that is refractory to or that relapses after immunochemotherapy and transplantation have a poor prognosis.
S. Schuster, J. Svoboda, E. Chong, S. Nasta, A. Mato, Ö. Anak, J. Brogdon, Iulian Pruteanu-Malinici, Vijay G. Bhoj, D. Landsburg, M. Wasik, B. Levine, S. Lacey, J. Melenhorst, D. Porter, C. June   +15 more
semanticscholar   +1 more source

Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma

Blood, 2021
Corticosteroids are used to treat the acute complications of chimeric antigen receptor (CAR) T-cell therapy. Strati et al examine the impact of corticosteroids on patient outcomes following CAR T-cell therapy for large B-cell lymphoma.
P. Strati, Saira S. Ahmed, F. Furqan, L. Fayad, Hun J. Lee, S. Iyer, R. Nair, L. Nastoupil, S. Parmar, M. Rodriguez, F. Samaniego, R. Steiner, Michael L. Wang, C. Pinnix, S. Horowitz, Lei Feng, R. Sun, Catherine M. Claussen, Misha C. Hawkins, Nicole A. Johnson, Prachee Singh, H. Mistry, S. Johncy, S. Adkins, P. Kebriaei, E. Shpall, Michael R. Green, C. Flowers, J. Westin, S. Neelapu   +29 more
semanticscholar   +1 more source

Organoids in pediatric cancer research

FEBS Letters, EarlyView.
Organoid technology has revolutionized cancer research, yet its application in pediatric oncology remains limited. Recent advances have enabled the development of pediatric tumor organoids, offering new insights into disease biology, treatment response, and interactions with the tumor microenvironment.
Carla Ríos Arceo, Jarno Drost
wiley   +1 more source

Activated iNKT cells enhance the anti-tumor effect of antigen specific CD8 T cells on mesothelin-expressing salivary gland cancer

BMC Cancer, 2018
Background Salivary gland cancers are not sensitive to conventional radiotherapy or chemotherapy regimens. Therefore, the development of a new treatment strategy is of critical importance for improving the prognosis.
Yuji Makita, Naoki Kunii, Daiju Sakurai, Fumie Ihara, Shinichiro Motohashi, Akane Suzuki, Toshinori Nakayama, Yoshitaka Okamoto   +7 more
doaj   +1 more source

Natural killer cell immunotherapy in glioblastoma

Discover Oncology, 2022
Glioblastoma (GBM) is one of the most difficult cancers to treat because GBM has the high therapeutic resistance. Recently, immunotherapies for GBM have been used instead of conventional treatments.
Hamed Hosseinalizadeh, Mehryar Habibi Roudkenar, Amaneh Mohammadi Roushandeh, Yoshikazu Kuwahara, Kazuo Tomita, Tomoaki Sato   +5 more
doaj   +1 more source

Structure‐forward targeting of claudins with synthetic binders

FEBS Letters, EarlyView.
Claudins form the paracellular barriers between epithelial and endothelial tissues at tight junctions and are targets for molecular binders with the goal of modulating barrier permeability. Claudin‐binding molecules are relevant in drug delivery or in altering claudin interactions with disease‐causing proteins.
Alex J. Vecchio
wiley   +1 more source

Chimeric Antigen Receptor T-Cell Therapy and Hematopoiesis

Cells, 2023
Chimeric Antigen Receptor (CAR) T-cell therapy is a promising treatment option for patients suffering from B-cell- and plasma cell-derived hematologic malignancies and is being adapted for the treatment of solid cancers. However, CAR T is associated with
Bryanna Reinhardt, Patrick Lee, Joshua P. Sasine   +2 more
doaj   +1 more source

Barriers to Chimeric Antigen Receptor T-Cell (CAR-T) Therapies in Clinical Practice

Pharmaceutical Medicine, 2022
Chimeric antigen receptor T-cell (CAR-T) therapy is a revolutionary cancer treatment modality where a patient’s own T cells are collected and engineered ex vivo to express a chimeric antigen receptor (CAR).
A. Gajra, Abigail Zalenski, Aishwarya Sannareddy, Y. Jeune-Smith, Kandice A. Kapinos, A. Kansagra   +5 more
semanticscholar   +1 more source

Engineering peptides into antibodies—opportunities and strategies for therapeutic innovation

FEBS Letters, EarlyView.
Peptides and antibodies occupy complementary therapeutic niches. Peptides recognize difficult targets in a compact format, while antibodies add specificity, long half‐life, and effector functions. This review examines strategies that merge both modalities—peptide grafting into loops, terminal and Fc fusions, and bioconjugation—highlighting how ...
Jinling Wang, Ruslana Romaniuk, Hristo L. Svilenov   +2 more
wiley   +1 more source